

Extraordinary general meeting in Newbury Pharmaceuticals AB (publ)

Extraordinary general meeting in Newbury Pharmaceuticals AB (publ) (the "Company") was held on 31 July 2024. Full information and documentation regarding the resolutions at the meeting are available at the Company's website, www.newburypharma.com. All resolutions made at the meeting correspond to the proposals presented in the notice.

Election of board members

The meeting resolved that the board of directors shall comprise of six members with no deputies and to elect Ramon Vila Ramos and Ivailo S. Georgiev as new members of the board of directors for the period until the end of the next annual general meeting.

Resolution regarding an incentive program, comprising a directed issue of warrants

The meeting resolved, in accordance with the shareholder proposal, on an incentive program comprising a directed issue of a maximum of 1,000,000 warrants to the board members Andreas Hedskog, Anil Okay, Johan Strömqvist and to Ramon Vila Ramos and Ivailo S. Georgiev who were elected as board members at the extraordinary general meeting. The issue of warrants will be made free of any consideration. Each participant shall have the right to receive a maximum of 200,000 warrants. Each participant has undertaken to waive its right to such board remuneration which was resolved by the 2024 annual general meeting.

Each warrant entitles the holder during the period from 1 September 2028 up to and including 30 November 2028 to subscribe for one (1) new share in the Company at a subscription price of SEK 5 per share.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

Press Release
31 July 2024 10:04:00 CEST



About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Extraordinary general meeting in Newbury Pharmaceuticals AB \(publ\)](#)